natgillin/translations-raw huggingface dataset:
Cmax and AUC (0–tlast) of iloprost after inhalation with Breelib were, however, still in the range of values observed with Ventavis 10 microgram/ml using other inhalers across different studies.
Cmax i AUC (0-tlast) iloprosta nakon inhalacije pomoću uređaja Breelib bile su ipak i dalje u rasponu vrijednosti zabilježenih uz primjenu lijeka Ventavis 10 mikrograma/ml pomoću drugih inhalatora u različitim ispitivanjima.
Cmax and AUC are approximately dose-proportional following administration of single and multiple doses.
Cmax i AUC približno su proporcionalni dozi nakon primjene jednostruke i višestrukih doza.
Cmax and the area under the plasma concentration-time curve (AUC) increased proportionally up to the highest doses studied (700 mg single-dose and once daily 400 mg multiple doses).
Cmax i površina ispod krivulje koncentracija-vrijeme (AUC) povisila se proporcionalno do najviših ispitivanih doza (700 mg pojedinačna doza i višestruke doze od 400 mg jednom na dan).
Cmax and the area under the plasma concentration-time curve were dose proportional.
Cmax i površina ispod krivulje koncentracija-vrijeme proporcionalni su dozi.
Cmax for R(+)-warfarin and S(-)-warfarin increased 14% and 15%, respectively.
Vrijednosti Cmax za R(+)-varfarin povećale su se 14% a za S(-)-varfarin 15%.
Cmax is dose-proportional between 5 and 10 mg.
U rasponu doza od 5 do 10 mg, Cmax je razmjeran primijenjenoj dozi.
Cmax of bosutinib in plasma increased 2.4-fold, 2-fold, and 1.5-fold, respectively, in Child-Pugh classes A, B, and C; and bosutinib AUC in plasma increased 2.3-fold, 2-fold, and 1.9-fold, respectively.
Cmax bosutiniba u plazmi porastao je za 2,4 puta, odnosno 2 puta i 1,5 puta u stadiju A, B odnosno C prema Child-Pugh, a AUC bosutiniba u plazmi porastao je za 2,3 puta, odnosno 2 puta i 1,9 puta.
Cmax of S- and R- warfarin increased 18% and 19%.
Cmax S- i R-varfarina je porastao za 18% odnosno 19%.
Cmax of the sachet was slightly higher (23%) compared with the capsule and did not meet the criteria for bioequivalence.
Cmax praška je bila neznatno veća (23%) u usporedbi s kapsulama, te ne udovoljava kriterije bioekvivalencije.
Cmax ↑ 1.04 (0.84-1.30)
Cmax ↑ 1,04 (0,84-1,30)
Cmax ↑ 1.10 (0.94-1.29)
Cmax ↑ 1,10 (0,94-1,29)
Cmax ↑ 1.10 (0.94-1.29)
Cmax ↑ 1,33 (1,21-1,46)
Cmax ↑ 1.14 (1.02-1.27)
Cmax ↑ 1,14 (1,02-1,27)
Cmax ↑ 1.15 (1.04-1.27) etravirine
Cmax ↑ 1,15 (1,04-1,27) etravirin
Cmax ↑ 1.17 (0.96-1.43)
antagonistima receptora H2
Cmax ↑ 1.17 (0.96-1.43)
Cmax ↑ 1,17 (0,96-1,43)
Cmax ↑ 1.19 (0.96-1.49)
Cmax ↑ 1,19 (0,96-1,49)
Cmax ↑ 1.26 (1.16-1.38)
Cmax ↑ 1,26 (1,16-1,38)
Cmax ↑ 1.29 (0.98-1.68)
Cmax  1,29 (0,98-1,68)
Cmax ↑ 1.30 (1.17-1.44)
Cmax ↑ 1,30 (1,17-1,44)
Cmax ↑ 1.33 (1.13-1.56) etravirine
Cmax ↑ 1,33 (1,13-1,56) etravirin
Cmax ↑ 1.33 (1.21-1.46)
Cmax ↑ 1,33 (1,21-1,46)
Cmax ↑ 1.46 (1.38-1.56)
Cmax ↑ 1,46 (1,38-1,56)
Cmax ↑ 1.47 (1.21-1.80)
 1,47 (1,21-1,80)
Cmax ↑ 1.62 (1.47-1.79)
Cmax ↑ 1,62 (1,47-1,79)
Cmax ↑ 1.62 (1.47-1.79) etravirine AUC ↔a Cmin ↔a
Cmax ↑ 1,62 (1,47-1,79)
Cmax ↑ 1.75 (1.60-1.91)
Cmax ↑ 1,75 (1,60-1,91)
Cmax ↑ 1.76 (1.60-1.94)
Cmax ↑ 1,10 (0,94-1,29)
Cmax ↑ 1.77 (1.20-2.60)
Cmax ↑ 1,77 (1,20-2,60)
Cmax ↓ 0.29 (0.22-0.40)
Cmax ↓ 0,29 (0,22-0,40)
Cmax ↓ 0.40 (0.28-0.57)
Cmax ↓ 0,40 (0,28-0,57)
Cmax ↓ 0.48 (0.43-0.54)
Cmax ↓ 0,48 (0,43-0,54)
Cmax ↓ 0.55 (0.40-0.75)
Cmax ↓ 0,55 (0,40-0,75)
Cmax ↓ 0.55 (0.40-0.75)
Cmin ↓ 0,87 (0,75-1,02)
Cmax ↓ 0.63 (0.53-0.74)
Cmax ↓ 0,63 (0,53-0,74)
Cmax ↓ 0.63 (0.53-0.74)
Cmax ↓ 0,90 (0,78-1,03)
Cmax ↓ 0.63 (0.53-0.75)
Cmax ↓ 0,63 (0,53-0,75)
Cmax ↓ 0.66 (0.57-0.77)
Cmax ↓ 0,66 (0,57-0,77)
Cmax ↓ 0.68 (0.57-0.82)
Cmax ↓ 0,68 (0,57-0,82)
Cmax ↓ 0.70 (0.64-0.78)
Cmax ↓ 0,70 (0,64-0,78)
Cmax ↓ 0.72 (0.55-0.94) dihydroartemisinin AUC ↓ 0.85 (0.75-0.97)
AUC ↓ 0,85 (0,75-0,97)
Cmax ↓ 0.72 (0.55-0.94) dihydroartemisinin AUC ↓ 0.85 (0.75-0.97)
Cmax ↓ 0,72 (0,55-0,94) dihidroartemisinin AUC ↓ 0,85 (0,75-0,97)
Cmax ↓ 0.75 (0.59-0.96)
Cmax ↓ 0,75 (0,59-0,96)
Cmax ↓ 0.76 (0.68-0.85)
Cmax ↓ 0,76 (0,68-0,85)
Cmax ↓ 0.81 (0.75-0.88)
Cmax ↓ 0,81 (0,75-0,88)
Cmax ↓ 0.84 (0.71-0.99) lumefantrine
Cmax ↓ 0,84 (0,71-0,99) lumefantrin
Cmax ↓ 0.85 (0.72-1.00)
Cmax ↓ 0,85 (0,72-1,00)
Cmax ↓ 0.88 (0.78-1.00) etravirine AUC ↔a Cmin ↔a
etravirin AUC ↔a Cmin ↔a
Cmax ↓ 0.89 (0.68-1.15)
Cmax ↓ 0,89 (0,68-1,15)
Cmax ↓ 0.90 (0.78-1.03)
Cmax ↓ 0,90 (0,78-1,03)
Cmax ↓ 0.90 (0.79-1.02)
Cmax ↓ 0,90 (0,79-1,02)
Cmax ↓ 0.94 (0.75-1.17)
Cmax ↓ 0,94 (0,75-1,17)
Cmax ↓ 0.95 (0.75-1.21) etravirine
Cmax ↓ 0,95 (0,75-1,21) etravirin
Cmax ↔ 0.89 (0.82-0.96)
Cmax ↔ 0,89 (0,82-0,96)
Cmax ↔ 0.89 (0.83-0.97)
Cmax ↔ 0,89 (0,83-0,97)
Cmax ↔ 0.89 (0.83-0.97)
Cmax ↔ 0,97 (0,93-1,02)
Cmax ↔ 0.92 (0.85-1.00) etravirine
Cmax ↔ 0,92 (0,85-1,00) etravirin
Cmax ↔ 0.93 (0.84-1.03)
Cmax ↔ 0,93 (0,84-1,03)
Cmax ↔ 0.93 (0.84-1.03)
Cmax ↔ 1,05 (0,98-1,12)
Cmax ↔ 0.97 (0.89-1.05)
Cmax ↔ 0,97 (0,89-1,05)
Cmax ↔ 0.97 (0.93-1.02)
Cmax ↔ 0,97 (0,93-1,02)
Cmax ↔ 1.00 (0.70-1.42)
Cmax ↔ 1,00 (0,70-1,42)
Cmax ↔ 1.02 (0.96-1.09)
Cmax ↑ 1,76 (1,60-1,94)
Cmax ↔ 1.02 (0.96-1.09)
Cmax ↔ 1,02 (0,96-1,09)
Cmax ↔ 1.04 (0.97-1.12)
Cmax ↔ 1,04 (0,97-1,12)
Cmax ↔ 1.05 (0.95-1.17)
Cmax ↔ 1,05 (0,95-1,17)
Cmax ↔ 1.05 (0.96-1.15)
Cmax ↔ 0,89 (0,83-0,97)
Cmax ↔ 1.05 (0.96-1.15)
Cmax ↔ 1,05 (0,96-1,15)
Cmax ↔ 1.05 (0.98-1.12)
BENZODIAZEPINI
Cmax ↔ 1.05 (0.98-1.12)
Cmax ↔ 1,05 (0,98-1,12)
Cmax ↔ 1.06 (0.95-1.20)
Cmax ↔ 1,02 (0,96-1,09)
Cmax ↔ 1.06 (0.95-1.20)
Cmax ↔ 1,06 (0,95-1,20)
Cmax ↔ 1.07 (0.94-1.23) etravirine
Cmax ↔ 1,07 (0,94-1,23) etravirin
Cmax ↔ 1.07 (1.02-1.13)
Cmax ↔ 1,07 (1,02-1,13)
Cmax ↔ 1.11 (1.06-1.17)
Cmax ↔ 1,11 (1,06-1,17)
Cmax ↔ 1.11 (1.06-1.17)
njegovom aktivnom
Cmax ↔ 1.16 (1.02-1.32)
Cmax ↔ 1,16 (1,02-1,32)
Cmax ↔a
KORTIKOSTEROIDI
Cmax  0% C24  6%
Cmax  0
Cmax  13% Cτ  22%
Cmax  13
Cmax  5% Cτ  8%
Cmax  5
Cmax 7%
Cmax 7% trimetoprim:
Cmax  43% Cτ 72% (induction of UGT1A1 and CYP3A enzymes)
Cmax  43% Cτ 72% (indukcija enzima UGT1A1 i CYP3A)
Cmax  72% (Complex binding to polyvalent ions)
Cmax  72% (stvaranje kompleksa s polivalentnim ionima)
Cmax, Cmin
ANTIARITMICI
Cmax, Cmin
SEDATIVI/HIPNOTICI
Cmax, Cmin with confidence intervals if availablea (mechanism)
AUC, Cmax, Cmin uz intervale pouzdanosti ako su dostupnia (mehanizam)
Cmax, Cmin with confidence intervals if availablea (mechanism)
podataka, uz hormonske
Cmax, Cmin1
ANTIDEPRESIVI
Cmax, Cmin1
OPIOIDNI ANALGETICI
Cmax: +--
Cmax: ↔
Cmax: +--**
Cmax: ↔
Cmax: 0 12% (0 1 to 0 26)
Cmax: ↓ 12% (↓ 1 do ↓ 26) 2-hidroksi atorvastatin:
Cmax: 0 17% (0 6 to 0 26)b
Cmax: ↓ 17% (↓ 6 do ↓ 26) b
Cmax: 0 18% (0 59 to j 12)
Cmax: ↓ 18% (↓ 59 do ↑ 12)
Cmax: 0 20% (0 11 to 0 28)
Cmax: ↓ 20% (↓ 11 do ↓ 28)
Cmax: 0 20% (0 15 to 0 24)
Cmax: ↓ 20% (↓ 15 do ↓ 24)
Cmax: 0 20% (0 2 to 0 26)
Cmax: ↓ 20% (↓ 2 do ↓ 26)
Cmax: 0 21% (0 15 to 0 26)
Cmax: ↓ 21% (↓ 15 do ↓ 26)
Cmax: 0 24% (0 18 to 0 30)
Cmax: ↓ 24% (↓ 18 do ↓ 30)
Cmax: 0 28% (0 7 to 0 44)
Cmax: ↓ 28% (↓ 7 do ↓ 44)
Cmax: 0 29% (0 15 to 0 40)
Cmax: ↓ 29% (↓ 15 do ↓ 40)
Cmax: 0 34% (0 21 to 0 47)
Cmax: ↓ 34% (↓ 21 do ↓ 47) hidroksibupropion:
Cmax: 0 35% (0 12 to 0 52)
Cmax: ↓ 35% (↓ 12 do ↓ 52)
Cmax: 0 37% (0 20 to 0 51)
Cmax: ↓ 37% (↓ 20 do ↓ 51)
Cmax: 0 44% (0 20 to 0 61)
Cmax: ↓ 44% (↓ 20 to ↓ 61)
Cmax: 0 45% (0 25 to 0 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25 do ↓ 59) (indukcija CYP3A4)
Cmax: 0 45% (UDP-G induction)
Cmax: ↓ 45
Cmax: 0 46% (0 39 to 0 52)
Cmax: ↓ 46% (↓ 39 do ↓ 52)
Cmax: 0 47% (0 9 to 0 51)
Cmax: ↓ 47% (↓ 9 do ↓ 51)
Cmax: 0 51% (0 32 to 0 58)
Cmax: ↓ 51% (↓ 32 do ↓ 58)
Cmax: 0 51% (0 37 to 0 62)
Cmax: ↓ 51% (↓ 46 do ↓ 56)
Cmax: 0 60% (0 50 to 0 68)
Cmax: ↓ 60% (↓ 50 do ↓ 68)
Cmax: 0 62% (0 55 to 0 78) (CYP3A4 induction)
Cmax: ↓ 62% (↓ 55 do ↓ 78) (indukcija CYP3A4)
Cmax: 0 64% (0 57 to 0 69)
Cmax: ↓ 64% (↓ 57 do ↓ 69)
Cmax: 0 80% (0 77 to 0 83)
Cmax: ↓ 80% (↓ 77 do ↓ 83)
Cmax: 0.77 (0.70, 0.85)
Cmax:: 0,77 (0,70, 0,85)
Cmax: 0.97 (0.80, 1.17)
Cmax: 0,97 (0,80, 1,17)
Cmax: 051% (046 to 056)
primjena alternative
Cmax: 1.03 (0.84, 1.25)
Cmax: 1,03 (0,84, 1,25)
Cmax: 1.29 (1.07, 1.57)
Cmax: 1,29 (1,07, 1,57)
Cmax: 1.65 (1.52, 1.80)
Cmax: 1,65 (1,52; 1,80)
Cmax: j 11% (j 6 to j 16)
Cmax: ↑ 11% (↑ 6 do ↑ 16)
Cmax: j 15%
Cmax: ↑ 15% (inhibicija CYP3A4)
Cmax: j 16% (j 2 to j 32)
Cmax: ↑ 16% (↑ 2 do ↑ 32)
Cmax: j 16% (j 6 to j 26)
Cmax: ↑ 16% (↑ 6 do ↑ 26)
Cmax: j 23% (0 1 to j 53) * Efavirenz:
Cmax: ↑ 23% (↓ 1 do ↑ 53)
Cmax: j 38% Voriconazole:
Cmax: ↑ 38
Cmax: j 50% (j 20 to j 80) (CYP2B6 induction)
Cmax: ↑ 50% (↑ 20 do ↑ 80)
Cmax: ↑ 1.2-fold
Cmax: ↑ 1,2 puta
Cmax: ↑ 10%
Cmax:↑ 10
Cmax: ↑ 102% (↓ 96 to ↑ 108) Cmin: NC
Cmax: ↑ 102% (od ↓ 96 do ↑ 108) Cmin: NI
Cmax: ↑ 102% (↓ 96 – ↑ 108) Cmin: NC
Cmax: ↑ 102% (↓ 96 – ↑ 108)
Cmax: ↑ 11 % (↑ 3 to ↑ 19)
Cmax: ↑ 11% (↑ 3 do ↑ 19)
Cmax: ↑ 11 % (↑ 6 to ↑ 16)
Cmax: ↑ 11% (↑ 6 do ↑ 16)
Cmax: ↑ 11% (↑ 6 to ↑ 16)
Cmax: ↑ 11% (↑ 6 do ↑ 16)
Cmax: ↑ 14% (↑ 4 to ↑ 26)
Cmax: ↑ 14% (↑ 4 do ↑ 26)
Cmax: ↑ 15%
Cmax: ↑ 15% (inhibicija CYP3A4)
Cmax: ↑ 15%
Cmax: ↓ 15
Cmax: ↑ 15% (CYP3A4 inhibition)
Cmax: ↑ 15% (inhibicija CYP3A4)
Cmax: ↑ 16 % (↑ 2 to ↑ 32)
Cmax: ↑ 16% (↑ 2 do ↑ 32)
Cmax: ↑ 16 % (↑ 6 to ↑ 26)
Cmax: ↑ 16% (↑ 6 do ↑ 26)
Cmax: ↑ 16 % (↑ 6 to ↑ 26)
Cmax: ↓ 20% (↓ 2 do ↓ 26)
Cmax: ↑ 16% (↑ 2 to ↑ 32)
Cmax: ↑ 16% (↑ 2 do ↑ 32)
Cmax: ↑ 16% (↑ 6 to ↑ 26)
Cmax: ↑ 16% (↑ 6 do ↑ 26)
Cmax: ↑ 21 % (↑ 10 to ↑ 33)
AUC: ↑ 20% (↑ 8 do ↑ 34)
Cmax: ↑ 21 % (↑ 10 to ↑ 33)
Cmax: ↑ 21% (↑ 10 do ↑ 33)
Cmax: ↑ 21% (↑ 10 to ↑ 33)
Cmax: ↑ 21% (↑ 10 do ↑ 33)
Cmax: ↑ 23 % (↓ 1 to ↑ 53) *
Cmax: ↑ 23% (↓ 1 do ↑ 53)
Cmax: ↑ 23% (↓ 1 to ↑ 53) *
Cmax: ↑ 23% (↓ 1 do ↑ 53)
Cmax: ↑ 3.0 fold
Cmax: ↑ 3,0 puta
Cmax: ↑ 3.4-fold
Cmax: ↑ 3,4 puta
Cmax: ↑ 3.5-fold
Cmax: ↑ 3,5 puta
Cmax: ↑ 30% Inhibition of CYP3A
Cmax: ↑ 30% Inhibicija CYP3A
Cmax: ↑ 38 %
AUC: ↑ 44
Cmax: ↑ 4.1-fold Sirolimus (rapamycin): AUC: ↑ 10.9-fold Cmax: ↑ 4.4-fold
Cmax: ↑ 4,1 puta Sirolimus (rapamicin): AUC: ↑ 10,9 puta Cmax: ↑ 4,4 puta
Cmax: ↑ 4.7-fold
Cmax: ↑ 4,7 puta
Cmax: ↑ 4.7-fold
hipertenzije:
Cmax: ↑ 41% Cmin: ND
Cmax: ↑ 41% Cmin: NO
Cmax: ↑ 47% (↑ 37 to ↑ 58)
Cmax: ↑ 47% (od ↑ 37 do ↑ 58)
Cmax: ↑ 49 % (↑ 32 to ↑ 69)
Cmax: ↑ 49% (↑ 32 do ↑ 69)
Cmax: ↑ 49% (↑ 32 to ↑ 69)
Cmax: ↑ 49% (↑ 32 do ↑ 69)
Cmax: ↑ 49% (↑ 32 to ↑ 69) Efavirenz:
Cmax: ↑ 49% (↑ 32 do ↑ 69) efavirenz:
Cmax: ↑ 5% (↓ 3 to ↑ 14) Cmin: NC
Cmax: ↑ 5% (od ↓ 3 do ↑ 14) Cmin: NI
Cmax: ↑ 5% (↓ 3 – ↑ 14) Cmin: NC
Cmax: ↑ 3% (↓ 3 – ↑ 9)
Cmax: ↑ 50% (↑ 20 to ↑ 80) (CYP2B6 induction)
Cmax: ↑ 50% (↑ 20 do ↑ 80)
Cmax: ↑ 50% (↑ 20 to ↑ 80) (CYP2B6 induction)
Cmax: ↑ 50% (↑ 20 to ↑ 80) (CYP2B6 indukcija)
Cmax: ↑ 6-fold
Cmax: ↑ 4,7 puta
Cmax: ↑ 64% (mechanism of interaction unknown)
Cmax: ↑ 64% (nije poznat mehanizam interakcije)
Cmax: ↑ 64% (mechanism of interaction unknown) Tenofovir:
Cmax: ↑ 64% (mehanizam interakcije nije poznat) tenofovir:
Cmax: ↑ 68% (↑ 54 to ↑ 84)
Cmax: ↑ 68% (od ↑ 54 do ↑ 84)
Cmax: ↑ 7% (↓ 6 to ↑ 22) Cmin: NC
Cmax: ↑ 7% (od ↓ 6 do ↑ 22) Cmin: NI
Cmax: ↑ 7% (↓ 6 – ↑ 22) Cmin: NC
Cmax: ↑ 7% (↓ 6 – ↑ 22)
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmax: ↑ 79% (od ↑ 56 do ↑ 104)
Cmax: ↑1.6-fold
Cmax: ↑1,6 puta
Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NC
Cmax: ↓ 1% (od ↓ 7 do ↑ 6) Cmin: NI
Cmax: ↓ 1% (↓ 7 – ↑ 6) Cmin: NC
Cmax: ↓ 1% (↓ 7 – ↑ 6)
Cmax: ↓ 11% (↓ 17 to ↓ 5) Cmin: NC
Cmax: ↓ 11% (od ↓ 17 do ↓ 5) Cmin: NI
Cmax: ↓ 11% (↓ 20 to ↑ 1) Cmin: NC
Cmax: ↓ 11% (od ↓ 20 do ↑ 1) Cmin: NI
Cmax: ↓ 12 % (↓ 1 to ↓ 26) 2-hydroxy atorvastatin:
Cmax: ↓ 12% (↓ 1 do ↓ 26) 2-hidroksi atorvastatin:
Cmax: ↓ 12% (↓ 1 to ↓ 26)
Cmax: ↓ 12% (↓ 1 do ↓ 26)
Cmax: ↓ 12% (↓ 1 to ↓ 26) 2-hydroxy atorvastatin:
Cmax: ↓ 12% (↓ 1 do ↓ 26) 2-hidroksiatorvastatin:
Cmax: ↓ 13 % (↓ 0 to ↓ 23) 4-hydroxy atorvastatin: AUC: ↓ 4 % (↓ 0 to ↓ 31)
Cmax: ↓ 13% (↓ 0 do ↓ 23) 4-hidroksi atorvastatin: AUC: ↓ 4% (↓ 0 do ↓ 31)
Cmax: ↓ 13% (↓ 0 to ↓ 23)
Cmax: ↓ 13% (↓ 0 do ↓ 23)
Cmax: ↓ 13% (↓ 0 to ↓ 23) 4-hydroxy atorvastatin: AUC: ↓ 4% (↓ 0 to ↓ 31)
Cmax: ↓ 13% (↓ 0 do ↓ 23) 4-hidroksiatorvastatin: AUC: ↓ 4% (↓ 0 do ↓ 31)
Cmax: ↓ 13% Cmin: ND
Cmax: ↓ 13% Cmin: NO
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmax: ↓ 14 % (↓ 3 do ↓ 24)
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmax: ↓ 14% (↓ 3 do ↓ 24)
Cmax: ↓ 15% (CYP3A4 induction) Efavirenz:
Cmax: ↓ 15% (indukcija CYP3A4) efavirenz:
Cmax: ↓ 16% (↓ 22 to ↓ 10)
Cmax: ↓ 16% (od ↓ 22 do ↓ 10)
Cmax: ↓ 17% (↓ 6 to ↓ 26) b
Cmax: ↓ 17% (↓ 6 do ↓ 26) b
Cmax: ↓ 18 % (↓ 59 to ↑ 12)
Cmax: ↓ 18% (↓ 59 do ↑ 12)
Cmax: ↓ 18% (↓ 59 to ↑ 12)
Cmax: ↓ 18% (↓ 59 do ↑ 12)
Cmax: ↓ 18% (↓ 59 to ↑ 12)
Cmax: ↓ 18% (↓ 59 do ↓ 12)
Cmax: ↓ 19% (↓ 40 to ↑ 10) GS-3310071:
Cmax: ↓ 19% (od ↓ 40 do ↑ 10) GS-3310071:
Cmax: ↓ 20 % (↓ 11 to ↓ 28)
Cmax: ↓ 20% (↓ 11 do ↓ 28)
Cmax: ↓ 20 % (↓ 15 to ↓ 24)
Cmax: ↓ 20% (↓ 15 do ↓ 24)
Cmax: ↓ 20 % (↓ 15 to ↓ 24)
Cmax: ↓ 29% (↓ 15 do ↓ 40)
Cmax: ↓ 20 % (↓ 2 to ↓ 26)
Cmax: ↓ 20% (↓ 2 do ↓ 26)
Cmax: ↓ 20 % (↓ 2 to ↓ 26)
Cmax: ↓ 62% (↓ 55 do ↓ 78)
Cmax: ↓ 20% (↓ 11 to ↓ 28)
Cmax: ↓ 20% (↓ 11 do ↓ 28)
Cmax: ↓ 20% (↓ 15 to ↓ 24)
Cmax: ↓ 20% (↓ 15 do ↓ 24)
Cmax: ↓ 21 % (↓ 15 to ↓ 26)
Cmax: ↓ 21% (↓ 15 do ↓ 26)
Cmax: ↓ 21% (↓ 15 to ↓ 26)
Cmax: ↓ 21% (↓ 15 do ↓ 26)
Cmax: ↓ 21% Dihydroartemisinin (active metabolite):
Cmax: ↓ 21% dihidroartemisinin (aktivni metabolit):
Cmax: ↓ 21% Dihydroartemisinin:
artemeter: AUC: ↓ 51
Cmax: ↓ 21% Dihydroartemisinin: AUC: ↓ 46%
Cmax: ↓ 21% dihidroartemisinin: AUC: ↓ 46
Cmax: ↓ 23% (↓ 30 to ↑ 16) Efavirenz:
Cmax: ↓ 23% (od ↓ 30 do ↑ 16) efavirenz:
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmax: ↓ 24 % (↓ 15 do ↓ 32)
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmax: ↓ 24% (↓ 15 do ↓ 32)
Cmax: ↓ 24% (↓ 18 to ↓ 30)
Cmax: ↓ 24% (↓ 18 do ↓ 30)
Cmax: ↓ 24% (↓ 44 to ↓ 12) Cmin: NC
Cmax: ↓ 24% (od ↓ 44 do ↓ 12) Cmin: NI
Cmax: ↓ 24% (↓ 44 –↓ 12) Cmin: NC
Cmax: ↓ 24% (↓ 44 –↓ 12)
Cmax: ↓ 26 % (↓ 15 to ↓ 35)
Cmax: ↓ 26% (↓ 15 do ↓ 35)
Cmax: ↓ 26 % (↓ 15 to ↓ 35) Clarithromycin
Cmax: ↓ 26% (↓ 15 do ↓ 35)
Cmax: ↓ 26% (↓ 15 to ↓ 35)
Cmax: ↓ 26% (↓ 15 do ↓ 35)
Cmax: ↓ 28 % (↓ 7 to ↓ 44)
Cmax: ↓ 28% (↓ 7 do ↓ 44)
Cmax: ↓ 28 % (↓ 7 to ↓ 44)
Cmax: ↓ 47% (↓ 9 do ↓ 51)
Cmax: ↓ 28% (↓ 50 to ↑ 5)
Cmax: ↓ 28% (↓ 50 do ↑ 5)
Cmax: ↓ 28% (↓ 7 to ↓ 44)
Cmax: ↓ 28% (↓ 7 do ↓ 44)
Cmax: ↓ 29 % (↓ 15 to ↓ 40)
Cmax: ↓ 29% (↓ 15 do ↓ 40)
Cmax: ↓ 29 % (↓ 15 to ↓ 40)
Cmax: ↓ 34% (↓ 21 do ↓ 47) hidroksibupropion:
Cmax: ↓ 29% (↓ 15 to ↓ 40)
Cmax: ↓ 29% (↓ 15 do ↓ 40)
Cmax: ↓ 31% Induction of CYP3A
Cmax: ↓ 31% Indukcija CYP3A
Cmax: ↓ 32 % (↓ 15 to ↓ 46)
Cmax: ↓ 32% (↓ 15 do ↓ 46)
Cmax: ↓ 32% (↓ 15 to ↓ 46)
Cmax: ↓ 32% (↓ 15 do ↓ 46)
Cmax: ↓ 33% (Mechanism unknown)
Cmax: ↓ 33% (Nepoznati mehanizam) Izavukonazol:
Cmax: ↓ 34% (↓ 21 to ↓ 47) Hydroxybupropion:
Cmax: ↓ 28% (↓ 7 do ↓ 44)
Cmax: ↓ 34% (↓ 21 to ↓ 47) Hydroxybupropion:
Cmax: ↓ 34% (↓ 21 do ↓ 47) hidroksibupropion:
Cmax: ↓ 34% (↓ 41 to ↑ 25)
Cmax: ↓ 34% (od ↓ 41 do ↑ 25)
Cmax: ↓ 35 % (↓ 12 to ↓ 52)
Cmax: ↓ 35% (↓ 12 do ↓ 52)
Cmax: ↓ 35% (↓ 12 to ↓ 52)
Cmax: ↓ 35% (↓ 12 do ↓ 52)
Cmax: ↓ 36 % (UGT1A1 induction)
Cmax: ↓ 36% (indukcija UGT1A1)
Cmax: ↓ 36% (UGT1A1 induction)
Cmax: ↓ 36% (indukcija UGT1A1)
Cmax: ↓ 37 % (↓ 20 to ↓ 51)
Cmax: ↓ 37% (↓ 20 do ↓ 51)
Cmax: ↓ 37% (↓ 20 to ↓ 51)
Cmax: ↓ 37% (↓ 20 do ↓ 51)
Cmax: ↓ 37% (↓ 48 to ↓ 25)
Cmax: ↓ 37% (od ↓ 48 do ↓ 25)
Cmax: ↓ 38%
Cmax: ↓ 44% (↓ 20 to ↓ 61)
Cmax: ↓ 38% Lumefantrine: AUC: ↓ 21%
Cmax: ↓ 38% lumefantrin: AUC: ↓ 21
Cmax: ↓ 4% (CYP3A4 inhibition)
Cmax: ↓ 4% (Inhibicija CYP3A4)
Cmax: ↓ 4% (↓ 9 to ↑ 2) Cmin: NC
Cmax: ↓ 4% (od ↓ 9 do ↑ 2) Cmin: NI
Cmax: ↓ 4% (↓ 9 – ↑ 2) Cmin: NC
Cmax: ↓ 4% (↓ 9 – ↑ 2)
Cmax: ↓ 44% (↓ 20 to ↓ 61) Proguanil:
Cmax: ↓ 44% (↓ 20 do ↓ 61) Progvanil:
Cmax: ↓ 45 % (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25 do ↓ 59) (indukcija CYP3A4)
Cmax: ↓ 45% (UDP-G induction)
(indukcija UDP-G)
Cmax: ↓ 45% (UDP-G induction)
Cmax: ↓ 45% (indukcija UDP-G)
Cmax: ↓ 45% (↓ 25 to ↓ 59) (CYP3A4 induction)
Cmax: ↓ 45% (↓ 25 do ↓ 59) (indukcija CYP3A4)
Cmax: ↓ 46 % (↓ 39 to ↓ 52)
Cmax: ↓ 46% (↓ 39 do ↓ 52)
Cmax: ↓ 46%
Valproat: ↓
Cmax: ↓ 46% (↓ 39 to ↓ 52)
Cmax: ↓ 46% (↓ 39 do ↓ 52)
Cmax: ↓ 47 % (↓ 9 to ↓ 51)
Cmax: ↓ 47% (↓ 9 do ↓ 51)
Cmax: ↓ 47 % (↓ 9 to ↓ 51)
Cmax: ↓ 51% (↓ 32 do ↓ 58)
Cmax: ↓ 47%
AUC: ↓ 55
Cmax: ↓ 47% (↓ 9 to ↓ 51)
Cmax: ↓ 47% (↓ 9 do ↓ 51)
Cmax: ↓ 5% (↓ 11 to ↑ 1) Cmin: NC
Cmax: ↓ 5% (od ↓ 11 do ↑ 1) Cmin: NI
Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC
Cmax: ↓ 19% (od ↓ 40 do ↑ 10)
Cmax: ↓ 5% (↓ 27 to ↑ 24) Cmin: NC
Cmax: ↓ 5% (od ↓ 27 do ↑ 24) Cmin: NI
Cmax: ↓ 5% (↓ 27 – ↑ 24) Cmin: NC
Cmax: ↓ 5% (↓ 11 – ↑ 1)
Cmax: ↓ 51 % (↓ 32 to ↓ 58)
Cmax: ↓ 51% (↓ 32 do ↓ 58)
Cmax: ↓ 51 % (↓ 37 to ↓ 62)
Cmax: ↔ 8
Cmax: ↓ 51 % (↓ 37 to ↓ 62) Efavirenz concentrations not measured, no effect is expected.
Cmax: ↓ 51% (↓ 37 do ↓ 62) Koncentracije efavirenza nisu mjerene, ne očekuje se nikakav učinak.
Cmax: ↓ 51% (↓ 32 to ↓ 58)
Cmax: ↓ 51% (↓ 32 do ↓ 58)
Cmax: ↓ 51% (↓ 37 to ↓ 62) Efavirenz concentrations not measured, no effect is expected.
Cmax: ↓ 51% (↓ 37 do ↓ 62) Koncentracije efavirenza nisu mjerene, ne očekuje se nikakav učinak.
Cmax: ↓ 51% (↓ 46 to ↓ 56)
Cmax: ↓ 51% (↓ 46 do ↓ 56)
Cmax: ↓ 52% (Mechanism unknown)
Cmaks: ↓ 52% (Nepoznati mehanizam)
Cmax: ↓ 6% (↓ 13 to ↑ 0)
Cmax: ↓ 23% (od ↓ 30 do ↑ 16)
Cmax: ↓ 6% (↓ 13 to ↑ 0)
Cmax: ↓ 6% (od ↓ 13 do ↑ 0)
Cmax: ↓ 60 % (↓ 50 to ↓ 68)
Cmax: ↓ 60% (↓ 50 do ↓ 68)
Cmax: ↓ 60% (↓ 50 to ↓ 68)
Cmax: ↓ 60% (↓ 50 do ↓ 68)
Cmax: ↓ 61 %
Cmax: ↓ 61% efavirenz:
Cmax: ↓ 62 % (↓ 55 to ↓ 78) (CYP3A4 induction)
Cmax: ↓ 62% (↓ 55 do ↓ 78) (indukcija CYP3A4)
Cmax: ↓ 62% (↓ 55 to ↓ 78) (CYP3A4 induction)
Cmax: ↓ 62% (↓ 55 do ↓ 78) (indukcija CYP3A4)
Cmax: ↓ 64 % (↓ 57 to ↓ 69)
Cmax: ↓ 64% (↓ 57 do ↓ 69)
Cmax: ↓ 64% (↓ 57 to ↓ 69)
Cmax: ↓ 64% (↓ 57 do ↓ 69)
Cmax: ↓ 69% Induction of CYP3A
Cmax: ↓ 69% Indukcija CYP3A
Cmax: ↓ 7% (↓ 13 to ↓ 0) Cmin: NC
Cmax: ↓ 7% (od ↓ 13 do ↓ 0) Cmin: NI
Cmax: ↓ 7% (↓ 13 – ↓ 0) Cmin: NC
Cmax: ↓ 7% (↓ 13 – ↓ 0)
Cmax: ↓ 7% (↓ 22 to ↑ 11) Cmin: NC
Cmax: ↓ 7% (od ↓ 22 do ↑ 11) Cmin: NI
Cmax: ↓ 76 % (↓ 63 to ↓ 79) Simvastatin acid:
Cmax: ↓ 76% (↓ 63 do ↓ 79)
Cmax: ↓ 76% (↓ 63 to ↓ 79)
Cmax: ↓ 76% (↓ 63 do ↓ 79)
Cmax: ↓ 80 % (↓ 77 to ↓ 83)
Cmax: ↓ 80% (↓ 77 do ↓ 83)
Cmax: ↓ 80% (↓ 77 to ↓ 83)
Cmax: ↓ 80% (↓ 77 do ↓ 83)
Cmax: ↔
150 mg i.m.)
Cmax: ↔
antacid/efavirenz
Cmax: ↔
Pitavastatin
Cmax: ↔ (CYP3A4 induction)
Cmax: ↔ (indukcija CYP3A4)
Cmax: ↔ 1.01 Maraviroc concentrations not measured, no interaction expected.
Cmax:  1,01 Koncentracije maraviroka nisu
Cmax: ↔ 1.21
AUC:  1,18 Midazolam.
Cmax: ↔ 11% (CYP3A induction - effect on boceprevir)
Cmax: ↔ 11% (indukcija CYP3A - utjecaj na
Cmax: ↔ 11% (CYP3A induction - effect on boceprevir)
Cmax: ↔ 11% (indukcija CYP3A - utjecaj na boceprevir)
Cmax: ↔ 11% (CYP3A induction - effect on boceprevir)
Cmax: ↔ 11% (indukcija CYP3A– učinak na boceprevir)
Cmax: ↔ 11% (CYP3A induction - effect on boceprevir)
Nema utjecaja (↔) jednako smanjenje
Cmax: ↔ 8%
Cmax: ↔
Cmax: ↔ Cmin: ↑ 91%
Cmax: ↑ 25% Cmin: ↔
Cmax: ↔ Emtricitabine: AUC: ↔
Cmax: ↔ emtricitabin: AUC: ↔
Cmax: ↔ Ketoconazole AUC: ↑ 2.7-fold Cmax:↑ 1.5-fold (CYP3A4 enzyme inhibition by ritonavir)
Cmax: ↔ ketokonazol AUC: ↑ 2,7 puta Cmax: ↑ 1,5 puta (inhibicija enzima CYP3A4 ritonavirom)
Cmax= maximum plasma concentration t1/2 effective= effective half-lives aValues are estimated from population PK analysis bN=353 refers to all the subjects included in the population PK analysis cValues are obtained from published data [Schaaf LJ et al.
Cmax= maksimalna koncentracija u plazmi t1/2 efektivni= efektivni poluvijek aVrijednosti procijenjene iz populacijske farmakokinetičke analize bN=353 se odnosi na sve ispitanike uključene u populacijsku farmakokinetičku analizu cVrijednosti su preuzete iz objavljenih podataka [Schaaf LJ et al.
CMF on day 1 and 8 every 4 weeks for 3 cycles
CMF 1. i 8. dana svaka 4 tjedna u 3 ciklusa
CMF on day 1 and 8 every 4 weeks for 3 cycles
CMF 1. i 8. dana, svaka 4 tjedna u 3 ciklusa
CMH test p-value for response rate (versus imatinib 400 mg once daily)
p-vrijednost CMH* testa za stopu odgovora (u odnosu na 400 mg imatiniba jedanput na dan)
Cmin (mg/dl)/(mg/kg) (trough level)
Cmin (mg/dl)/(mg/kg) (najniža koncentracija)
Cmin (trough, g/l)
Cmin (najniže, g/l)
Cmin 0.32 (0.25-0.42)
Cmin 0,32 (0,25-0,42)
Cmin 0.44 (0.40-0.50)
smanjenja Cmin amprenavira kod
Cmin 0.48 (0.40-0.56)
Cmin 0,48 (0,40-0,56)
Cmin 0.53 (0.44-0.65)
Cmin 0,53 (0,44-0,65)
Cmin 0.58 (0.52-0.63)
Cmin 0,58 (0,52-0,63)
Cmin 0.58 (0.52-0.64) mechanism unknown
Cmin 0,58 (0,52-0,64)
Cmin 0.68 (0.63-0.74)
Cmin 0,68 (0,63-0,74)
Cmin 0.69 (0.64-0.75)
Cmin 0,69 (0,64-0,75)
Cmin 0.75 (0.61-0.92)
Cmin 0,75 (0,61-0,92)
Cmin 0.75 (0.66-0.86)
Cmin 0,75 (0,66-0,86)
Cmin 0.85 (0.75-0.98)
Cmin 0,85 (0,75-0,98)
Cmin 0.89 (0.67-1.18)
Cmin 0,89 (0,67-1,18)
Cmin 0.94 (0.87-1.00)
Cmax 0,85 (0,81-0,89)
Cmin 0.97 (0.86-1.10)
Cmin 0,97 (0,86-1,10)
Cmin 1.03 (0.93-1.14)
Cmin 1,03 (0,93-1,14)
Cmin 1.06 (0.87-1.30)
Cmin 1,06 (0,87-1,30)
Cmin 1.10 (0.97-1.24) induction of CYP3A by carbamazepine, and inhibition of CYP3A by telaprevir
Cmin 1,10 (0,97-1,24) indukcija CYP3A kabamazepinom, a inhibicija CYP3A telaprevirom
Cmin 1.14 (1.04-1.26)
Cmin 1,14 (1,04-1,26)
Cmin 1.41 (1.29-1.54) effect on P-gp transport in the gut
Cmin 1,41 (1,29-1,54) učinak na P-gp transport u crijevima
Cmin 1.78 (1.26-2.53)
Cmin 1,78 (1,26-2,53)
Cmin 1.85 (1.40-2.44)
Cmin 1,85 (1,40-2,44)
Cmin 1.93 (1.55-2.41)
Cmin 1,93 (1,55-2,41)
Cmin : 0 40%
Cmin: ↓ 40
Cmin in the setting of
uvjetima kombinirane terapije
Cmin ND
Cmin NP
Cmin ↑ 1.19 (1.13-1.26)
Cmin ↑ 1,19 (1,13-1,26)
Cmin ↑ 1.23 (0.87-1.75)
Cmin ↑ 1,23 (0,87-1,75)
Cmin ↑ 1.24 (0.96-1.59)
Cmin ↑ 1,24 (0,96-1,59)
Cmin ↑ 1.26 (1.12-1.42)
Cmin ↑ 1,26 (1,12-1,42)
Cmin ↑ 1.28 (1.13-1.45)
AUC↔ 1,11(1,02-1,20)
Cmin ↑ 1.46 (1.36-1.58)
Cmin ↑ 1,46 (1,36-1,58)
Cmin ↑ 1.52 (1.41-1.64)
Cmin ↑ 1,52 (1,41-1,64)
Cmin ↑ 1.77 (1.39-2.25)
Cmin ↑ 1,77 (1,39-2,25)
Cmin ↑ 2.09 (1.90-2.31)
Cmin ↑ 2,09 (1,90-2,31)
Cmin ↑ 5.27 (4.51-6.15)
Cmin ↑ 5,27 (4,51-6,15)
Cmin ↓ 0.12 (0.09-0.16)
Cmin ↓ 0,12 (0,09-0,16)
Cmin ↓ 0.18 (0.13-0.25)
Cmin ↓ 0,18 (0,13-0,25)
Cmin ↓ 0.47 (0.38-0.57)
Cmin ↓ 0,47 (0,38-0,57)
Cmin ↓ 0.51 (0.44-0.61)
Cmin ↓ 0,51 (0,44-0,61)
Cmin ↓ 0.55 (0.49-0.62)
Cmin ↓ 0,55 (0,49-0,62)
Cmin ↓ 0.61 (0.53-0.71)
Cmin ↓ 0,61 (0,53-0,71)
Cmin ↓ 0.62 (0.55-0.71)
Cmin ↓ 0,62 (0,55-0,71)
Cmin ↓ 0.63 (0.52-0.77)
Cmin ↓ 0,63 (0,52-0,77)
Cmin ↓ 0.65 (0.56-0.74)
Cmin ↓ 0,65 (0,56-0,74)
Cmin ↓ 0.65 (0.56-0.74)
Cmin ↓ 0,76 (0,66-0,87)
Cmin ↓ 0.66 (0.34-1.26)
Cmin ↓ 0,66 (0,34-1,26)
Cmin ↓ 0.71 (0.54-0.95)
Cmin ↓ 0,71 (0,54-0,95)
Cmin ↓ 0.71 (0.58-0.87)
Cmin ↓ 0,71 (0,58-0,87)
Cmin ↓ 0.76 (0.66-0.87)
Cmin ↓ 0,76 (0,66-0,87)
Cmin ↓ 0.78 (0.68-0.90)
Cmin ↓ 0,78 (0,68-0,90)
Cmin ↓ 0.78 (0.70-0.87)
Cmin ↓ 0,78 (0,70-0,87)
Cmin ↓ 0.78 (0.70-0.87)
rizika povećanja rifabutina i
Cmin ↓ 0.80 (0.46-1.38)
Cmin ↓ 0,80 (0,46-1,38)
Cmin ↓ 0.80 (0.73-0.88)
Cmin ↓ 0,80 (0,73-0,88)
Cmin ↓ 0.82 (0.67-1.01)
Cmin ↓ 0,82 (0,67-1,01)
Cmin ↓ 0.82 (0.73-0.91)
Cmin ↓ 0,82 (0,73-0,91)
Cmin ↓ 0.83 (0.71-0.97)
artemeter/lumefantrinom jer
Cmin ↓ 0.83 (0.71-0.97)
Cmin ↓ 0,83 (0,71-0,97)
Cmin ↓ 0.87 (0.75-1.02)
Cmin ↓ 0,87 (0,75-1,02)
Cmin ↓ 0.88 (0.66-1.17)
Cmin ↓ 0,88 (0,66-1,17)
Cmin ↔ 0.89 (0.81-0.98)
Cmin ↔ 0,89 (0,81-0,98)
Cmin ↔ 0.89 (0.81-0.98)
Cmin ↔ 1,10 (1,02-1,19)
Cmin ↔ 0.91 (0.84-0.98)
Cmin ↔ 0,91 (0,84-0,98)
Cmin ↔ 0.97 (0.83-1.15)
Cmin ↔ 0,97 (0,83-1,15)
Cmin ↔ 0.97 (0.86-1.10)
Cmin ↔ 0,97 (0,86-1,10)
Cmin ↔ 1.05 (0.90-1.22)
Cmin ↔ 1,05 (0,90-1,22)
Cmin ↔ 1.05 (0.93-1.18)
Cmin ↔ 1,05 (0,93-1,18)
Cmin ↔ 1.07 (0.98-1.17)
Cmin ↔ 0,89 (0,81-0,98)
Cmin ↔ 1.07 (0.98-1.17)
Cmin ↔ 1,07 (0,98-1,17)
Cmin ↔ 1.08 (0.98-1.19)
Cmin ↔ 1,08 (0,98-1,19)
Cmin ↔ 1.08 (1.04-1.14)
Cmin ↔ 1,08 (1,04-1,14)
Cmin ↔ 1.08 (1.04-1.14)
lumefantrin
Cmin ↔ 1.09 (1.01-1.18)
Cmin ↔ 1,09 (1,01-1,18)
Cmin ↔ 1.10 (1.02-1.19)
Cmin ↔ 1,10 (1,02-1,19)
Cmin ↔ 1.17 (1.10-1.26)
Cmin ↔ 1,17 (1,10-1,26)
Cmin ↔a
Cmin NP
Cmin ↔a
dnevno
Cmin  54 % (-74%; -18%)
Cmin  36 % (-57%; -3%)
Cmin: +--
Cmin: ↔
Cmin: 0 25% (0 14 to 0 34)%
klaritromicin 14-hidroksimetabolit:
Cmin: 0 25% (0 14 to 0 34)%
Nema klinički značajnih farmakokinetičkih interakcija.
Cmin: 0 31%
Cmin: ↓ 31
Cmin: 0 32% (0 15 to 0 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15 do ↓ 46)
Cmin: 0 43% (0 18 to 0 60)
Cmin: ↓ 43% (↓ 18 do ↓ 60)
Cmin: 0 44% (0 27 to 0 58)
Cmin: ↓ 44% (↓ 27 do ↓ 58)
Cmin: 0 44% Efavirenz: AUC: +-- 20%
simeprevira s efavirenzom se ne
Cmin: 0 46% (0 31 to 0 58)
Cmin: ↓ 46% (↓ 31 do ↓ 58)
Cmin: 0 50% (0 40 to 0 59)b Efavirenz:
Cmin: ↓ 50% (↓ 40 do ↓ 59) b efavirenz:
Cmin: 0 50% (0 40 to 0 59)b Efavirenz:
sakvinavir/ritonavir/efavirenz